Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 4 Squamous Cell Carcinoma of Head and Neck 3 Esophageal Neoplasms 3 Prostatic Neoplasms 2 Neoplasms 2 Head and Neck Neoplasms 2 Carcinoma, Squamous Cell 2 Uterine Cervical Neoplasms 1 Urinary Bladder Neoplasms 1 Thymoma 1 Stomach Neoplasms 1 Sarcoma 1 Phyllodes Tumor 1 Lymphatic Metastasis 1 Liver Neoplasms 1 Laryngeal Neoplasms 1 Laryngeal Diseases 1 High-Risk Cancer 1 Endometrial Neoplasms 1 Carcinoma, Hepatocellular 1 Breast Cancer Radiotherapy 1

Interventions

Gemcitabine 157 Cisplatin 116 pembrolizumab 80 Nivolumab 42 Carboplatin 42 Paclitaxel 41 Mitomycin 41 Cystectomy 40 Docetaxel 38 atezolizumab 33 Magnetic Resonance Spectroscopy 31 durvalumab 30 Radiotherapy 29 BCG Vaccine 26 avelumab 24 Specimen Handling 24 Doxorubicin 23 enfortumab vedotin 22 Fluorouracil 20 Cystoscopy 20 Methotrexate 17 Vinblastine 16 Standard of Care 15 Filgrastim 14 Transurethral Resection of Bladder 13 Sunitinib 13 Ipilimumab 13 vinflunine 12 5-aminolevulinic acid hexyl ester 12 tremelimumab 11

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Urinary Bladder Neoplasms × Radiotherapy, Adjuvant × Clear all

NCT05445648 2022-12-28

CBPTMI

First Affiliated Hospital Xi'an Jiaotong University

Phase 2 Unknown

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡